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Abstract
Choline is an important methyl donor and a component of membrane phospholipids. In this study,
we tested the hypothesis that choline availability can modulate cell proliferation and the methylation
of genes that regulate cell cycling. In several other model systems, hypomethylation of cytosine bases
that are followed by a guanosine (CpG) sites in the promoter region of a gene is associated with
increased gene expression. We found that in choline-deficient IMR-32 neuroblastoma cells, the
promoter of the cyclin-dependent kinase inhibitor 3 gene (CDKN3) was hypomethylated. This
change was associated with increased expression of CDKN3 and increased levels of its gene product,
kinase-associated phosphatase (KAP), which inhibits the G1/S transition of the cell cycle by
dephosphorylating cyclin-dependent kinases. Choline deficiency also reduced global DNA
methylation. The percentage of cells that accumulated bromodeoxyuridine (proportional to cell
proliferation) was 1.8 times lower in the choline-deficient cells than in the control cells.
Phosphorylated retinoblastoma (p110) levels were 3 times lower in the choline-deficient cells than
in control cells. These findings suggest that the mechanism whereby choline deficiency inhibits cell
proliferation involves hypomethylation of key genes regulating cell cycling. This may be a
mechanism for our previously reported observation that stem cell proliferation in hippocampus
neuroepithelium is decreased in choline-deficient rat and mouse fetuses.
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Choline or its derivatives are important for the structural integrity of cell membranes, methyl
metabolism, cholinergic neurotransmission and transmembrane signaling, as well as for lipid-
cholesterol transport and metabolism (Zeisel and Blusztajn 1994). It is required for normal
brain development; dietary choline supplementation of rat and mouse dams increases stem cell
proliferation, while choline deficiency decreases stem cell proliferation in fetal hippocampus
and septum (Albright et al. 1999a,b). These changes have important functional effects, as pups
from choline-supplemented dams have enhanced memory (Meck et al. 1988; Meck and
Williams 1997a,b) and long-term potentiation (an electrophysiological property of the
hippocampus) (Jones et al. 1999). Pups born of choline-deficient mothers have decreased
memory (Meck and Williams 1999) and long-term potentiation (Montoya et al. 2000). The
mechanism whereby choline modulates cell proliferation and neurogenesis has not been
previously determined.
Choline is a major dietary source for labile methyl groups (Zeisel and Blusztajn 1994), and via
its metabolite betaine, acts as methyl donor to homocysteine to form methionine (Finkelstein
2000). Methionine is the precursor of S-adenosylmethionine (AdoMet), which is the
physiological substrate for protein and DNA methylation (Jeltsch 2002). Dietary choline and
methyl group deficiency not only deplete choline and choline metabolites in rats, but also
decrease AdoMet concentration (Shivapurkar and Poirier 1983; Zeisel et al. 1989), with
resulting hypomethylation of DNA (Locker et al. 1986; Bhave et al. 1988; Dizik et al. 1991;
Wainfan and Poirier 1992; Tsujiuchi et al. 1999). DNA methylation occurs at cytosine bases
that are followed by a guanosine (CpG sites) (Holliday and Grigg 1993) and influences many
cellular events, including gene transcription, genomic imprinting and genomic stability
(Jaenisch 1997; Jones and Gonzalgo 1997; Robertson and Wolffe 2000). In mammals, about
60–90% of 5′-CpG-3′ islands are methylated (Jeltsch 2002). When this modification occurs in
promoter regions, gene expression is altered (Bird et al. 1985; Bird 1986); increased
methylation is associated with gene silencing or reduced gene expression (Jeltsch 2002).
The effects of choline deficiency on cell proliferation and apoptosis have been noted in multiple
neuronal model systems (Albright et al. 1999b; Yen et al. 1999, 2001; Holmes-McNary et
al. 2001), with cell cycle arrest usually occurring in the G1/S and G2/M transitions (Holmes-
McNary et al. 2001). Cyclin-dependent kinase inhibitor 3 gene (CDKN3), via its protein
product kinase-associated phosphatase (KAP), is an important regulator of progression through
the cell cycle (Hannon et al. 1994; Barford 2001; Johnson et al. 2002). It regulates the
retinoblastoma protein (pRb) activation via a phosphorylation mechanism that is responsible
for G1 to S transition (Dyson 1998). We conducted these studies to determine whether
overexpression of CDKN3 resulted from hypomethylation of its promoter region during
choline deficiency.
Experimental procedures
All reagents were purchased from Sigma, St. Louis, MO, USA if not otherwise specified.
Cell culture
IMR-32 human neuroblastoma cells (ATCC, Manassas, VA, USA) at passage 57 were grown
in Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Gibco, Grand Island, NY, USA)
supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA) and 1% Antibiotic-
Antimycotic (Gibco) containing penicillin 10 000 units/mL, streptomycin 10 000 μg/mL and
amphotericin B. After cells reached 30% confluence, the medium was changed to a defined
medium containing DMEM/F12 without choline chloride (Atlanta Biologicals, Norcross, GA,
USA), with added 5 μM choline chloride (choline deficient, CD), 70 μM choline chloride
(control, CT) or 70 μM choline chloride + 5 μM 5-Azacytidine (5-Aza) and the following
ingredients (Yen et al. 1999): bovine serum albumin 0.08% (Invitrogen), linolenic acid 0.04%,
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sodium oleate 24 mg/4 L, phosphate-buffered saline (PBS) 80 mL/4 L, L-methionine 17.24
mg/L, sodium bicarbonate 2.2 g/L, HEPES 1.192 g/L, progesterone 0.62 mg/L, putresceine
16.6 mg/L, selenium 0.039 mg/L, L-thyroxine 0.4 mg/L, triiodothyronine 0.378 mg/L,
transferrin 100 mg/L, insulin 10 mg/L and 1% Antibiotic-Antimycotic. The cells were
incubated for 48 h either in CD, CT or 5-Aza defined medium, then harvested, washed three
times with PBS and pelleted for immediate use or stored at −80°C. For in situ immunostaining,
cells were grown in the same conditions but in plastic chamber slides (Nalge Nunc
International, Naperville, IL, USA).
Bromodeoxyuridine (BrdU) incorporation
The cells were incubated with 10 μM BrdU for 30 min prior to harvesting and fixed in 4%
paraformaldehyde in PBS. BrdU-positive cells were identified by immunohistochemistry using
a BrdU Staining Kit (Oncogene, San Diego, CA, USA) according to the manufacturer’s
protocol, where the positive cells were stained with diaminobenzoic acid (DAB) and all cells
were counterstained with methyl-green. Four plates of cells were used for each condition (CD
and CT, at 48 h of treatment). The slides were coded so that the investigator was blind to the
sample’s treatment, and were analyzed with an Olympus BX50 microscope at 40×
magnification. The BrdU-positive cells were reported as mean percent of the total number of
cells counted for each sample ± standard error of the mean.
Oligonucleotide microarray analysis
Total RNA (40 μg) was extracted from six plates for each condition (CD and CT, IMR-32 cells
at 48 h incubation) using TRIzol Reagent (Invitrogen), and the RNA concentration was verified
by spectrophotometry. The total RNA was reverse transcribed into cDNA with Cy3 (70 μM
choline as reference) or Cy5 (5 μM choline as experiment) monoreactive fluorophors using
the CyScribe First-Strand cDNA Labeling Kit (Amersham Biosciences, Inc., Piscataway, NJ,
USA). Finally, both cDNA samples were hybridized to a Compugen 20 000 spot V2 Human
Microarray (UNC Genomics Core, UNC, Chapel Hill, NC, USA). A total of three independent
experiments (three arrays) were performed. Purification of probes, hybridization (65°C,
overnight) and washing were carried out according to the protocol provided by the UNC
Genomics Core & Microarray Facility (http://genomicscore.unc.edu). Fluorescent images of
the microarrays were collected using a GenePix 4000 fluorescent scanner (Axon Instruments,
Inc., Union City, CA, USA). Gridding and primary data acquisition were performed using
GenePix Pro Microarray Acquisition software. Data normalization, statistics and other data
transformation were performed using GeneSpring 5.1 software (Silicon Genetics, Redwood
City, CA, USA). The normalization used the positive control spots for glyceraldehyde-
phosphate dehydrogenase (GAPD). Lowess normalization was used to compare with the
GAPD-normalization. Gene expression levels were considered significantly different between
CD- and CT-treated cells if we observed an average log(2) ratio of more than 1.45 or less than
−1.45 (CD/CT ratio above 2 or below 0.5).
Combined bisulfite restriction analysis (COBRA)
Genomic DNA was extracted from cells using a FlexGene DNA Kit (Qiagen, Valencia, CA,
USA). In the final step, the extracted DNA was resuspended in TE buffer (10 mM Tris, 0.1
mM EDTA, pH 8.0) and stored at − 20°C until used. COBRA was performed as previously
described (Xiong and Laird 1997). Briefly, 1 μg genomic DNA was treated with sodium
bisulfite followed by PCR amplification of the region of interest and restriction digestion.
Genomic DNA was modified using a CpGenome DNA Modification Kit (Intergen Co.,
Purchase, NY, USA). All primer pairs for PCR analysis of CDKN3 CpG island regions were
designed with reference to the H. sapiens chromosome 14 working draft sequence segment
(GenBank accession number NT025892) and purchased from Invitrogen. The primers designed
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for the amplification of wild DNA were: CDKN3/WL-1, 5′-
CCAGTGCCGCCTCCCTCTGC-3′ (anti-sense primer) and CDKN3/WU-1, 5′-
GGAGGGTGAGGCGGAGACT-3′ (sense primer). The primers for bisulfite-modified DNA
were: CDKN3/ML-1, 5′-CCAATACCACCTCCCTCTAC-3′ (anti-sense) and CDKN3/MU-1,
5′-GGAGGGTGAGGTGGAGATT-3′ (sense), and CDKN3/ML-2, 5′-
CCAATACCGCCTCCCTCTAC-3′ (anti-sense) and CDKN3/MU-2, 5′-
GGAGGGTGAGGCGGAGATT-3′ (sense). Wild and bisulfite-modified DNAs were
amplified by an initial incubation at 94°C for 2 min followed by 30 cycles (for wild DNA) or
40 cycles (for modified DNA) of 94°C for 30 s, 65°C for 30 s, 72°C for 1 min, and a final
extension at 72°C for 10 min using Platinum PCR SuperMix (Invitrogen). Aliquots (30 μL) of
the PCR-amplified products were digested with restriction enzymes, 40 units of BstU I at 60°
C for 4 h (5′…cg^cg…3′; New England Biolabs, Beverly, MA, USA). Then, the products were
subjected to electrophoresis on a 3% agarose gel and visualized by SYBR Green I (BMA).
Bisulfite sequence analysis
To confirm the changes in CDKN3 promoter methylation between CD and CT cells observed
using COBRA, bisulfite sequencing was performed on the CpG island spanning the position
−408 to −125 (numbered from the transcriptional start site). Primers were purchased from
Qiagen: CDKN3-UP (sense wild type), 5′-GCACTCCAGCCTGGGCAACAAGAG-3′;
CDKN3-UM (sense modified), 5′-GTATTTTAGTTTGGGTAATAAGAG-3′; CDKN3-LOW
(anti-sense wild type), 5′-TCTTCCAGCAACCAATCAGATCC-3′; CDKN3-LM (anti-sense
modified), 5′-TTTTTTAGTAATTAATTAGATTT-3′. Wild and bisulfite-modified DNAs
were amplified by an initial incubation at 94°C for 2 min followed by 40 cycles of 94°C for
30 s, 57°C for 60 s, 72°C for 1 min, and a final extension at 72°C for 10 min using Platinum
PCR SuperMix (Invitrogen). Four independent PCR samples from each treatment (CD, CT,
5-Aza), using bisulfite-modified or wild-type DNA template, were sequenced using an ABI
3100 DNA Sequencer (Applied Biosystems, Foster City, CA, USA) at the UNC-CH
Automated DNA Sequencing Facility. The products were sequenced in both directions using
both primers for each PCR product. Retrieved sequences were analyzed using the Chromas
2.23 software (Technelysium Ptd Ltd, Tewantin, Qld, Australia). Complete conversion of
cytosine to thymidine was confirmed as all cytosine from non-CG sites was converted to
thymidine. We identified unmethylated, methylated and incompletely methylated sites. The
latter sites were identified using the chromatograms where, while the sequence for the wild-
type DNA was unequivocally determined, the bisulfite-modified DNA PCR products presented
mixed signals for C and T nucleotides (in various proportions), indicating that in a given
sample, the site was methylated on some strands but not on others.
Protein preparation and western blot analysis
Four samples were used for each condition (CD and CT at 48 h). The cells were harvested,
washed three times in PBS and resuspended in lysis buffer [1% sodium dodecyl sulfate (SDS),
1.0 mM sodium ortho-vanadate, 10 mM Tris pH 7.4]. Protein concentration was determined
by the Lowry method (Lowry et al. 1951). A 10 μg aliquot of protein from each sample was
treated with 2× electrophoresis buffer (250 mM Tris pH 6.8, 4% SDS, 10% glycerol, 0.006%
bromophenol blue and 2% β-mercaptoethanol) and boiled for 5 min. The samples were loaded
on a polyacrylamide gel (Bio-Rad, Hercules, CA, USA) and subjected to electrophoresis for
50 min. The transfer was carried out on a nitrocellulose membrane (Amersham) at 8 V for 75
min (Spector et al. 1997). The membrane was incubated in blocking buffer (Sigma, B-6429)
for 2 h at room temperature (RT) and left overnight at 4°C in blocking buffer containing one
of the following antibodies: rabbit KAP (C-18), diluted 1 : 2000 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); mouse β-actin diluted 1 : 1000 (Abcam, Cambridge, MA, USA,
ab6276); mouse HRP-conjugated pRb (IF8) diluted 1 : 500 (Santa Cruz Biotechnology,
sc-102). The membranes were washed three times in PBS with 0.1% Tween 20. The samples
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for KAP and actin measurement were incubated for 2 h at room temperature with either a goat
anti-rabbit or a goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) diluted 1 : 2000 in
blocking buffer. After washing three times in PBS with 0.1% Tween 20 and washing once in
distilled water, the membranes were briefly exposed to a chemiluminescent agent, Luminol
(Santa Cruz Biotechnology). The final images were acquired by exposing the membrane to a
Kodak BioMax Film for 30–60 s. The film was scanned and the integrated optical densities of
the bands were measured using the ScionImage software (Scion Corporation, Frederick, MD,
USA).
Immunohistochemistry
IMR-32 cells grown in plastic chamber slides were fixed in 4% paraformaldehyde for 15 min
and subsequently washed in PBS. Two different sets of slides were blocked for 2 h at RT with
Blocking Buffer (Sigma, B-6429), then incubated overnight with retinoblastoma protein (pRb)
antibody (Santa Cruz Biotechnology, sc-102) and phosphorylated retinoblastoma protein
(ppRb) antibody, (Thr-160 specific Sc-1661; Santa Cruz Biotechnology), respectively, each
diluted 1 : 200 in blocking buffer. After the incubation the slides were rinsed in PBS with 0.1%
Tween 20 three times for 20 min each and incubated for 2 h at RT with fluorescent secondary
antibodies: Alexa-Fluor anti-mouse (Molecular Probes, A-21201) and Alexa-Fluor anti-goat
(Molecular Probes, A-21468). After 3 washes in PBS with 0.1% Tween 20, the slides were
incubated for 20 min in a PBS solution containing 4′, 6-diamidino-2-phenylindole (100 ng/100
mL) for nuclei counterstaining. Images were acquired with an Olympus BX50 microscope at
40× magnification, with optical filters for UV light and red channel (above 600 nm). The protein
levels were measured by assessing the Integrated Optical Density (IOD) of each image, divided
by the number of cells, using ScionImage software (Scion Corporation). Finally, the average
value of IOD/cell for each image from the same sample was computed. Four different slides
were used for each condition (CD and CT).
Global DNA methylation
Analysis was performed using a protocol described elsewhere (Hernandez-Blasquez et al.
2000). Briefly, after denaturing the DNA and non-specific blocking, a goat anti-5-
methylcytosine antibody (Megabase Research, Lincoln, NE, USA) was used to incubate
overnight the cells grown in chamber slides. A secondary fluorescent (mouse anti-goat,
Molecular Probes) was used, and images collected and data analyzed as previously described
(see immunohistochemistry section). Four samples from each treatment (CD, CT and 5-Aza)
were used.
Statistics
Students’ t-test was used (JMP 3.2.6, SAS Institute INC, Cary, NC, USA) to determine
statistical significance between the treatment group (CD) and control (CT) at 48 h for BrdU
incorporation, Western blot assay and immunohistochemistry, and between CD or 5-Aza and
CT, respectively, for global DNA methylation.
Results
DNA in CD cells was globally hypomethylated compared with CT cells (as determined by
immunofluorescence) after 48 h of exposure (1091 ± 42 in CD vs. 1979 ± 224 in CT; mean
integrated optical density per cell ± SEM; n = 4/treatment; p < 0.01 different) and the trend
persisted after 96 h (data not shown). 5-Aza-treated cells had the lowest global DNA
methylation among all three conditions after 48 h of exposure (866 ± 101; p < 0.01 different
from CT).
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CDKN3 has a CpG island in its promoter and first exon, and the primer sets used in this
experiment amplified the expected 522 bp product, which covered 44 CpG sites containing
several sites for cutting by BstU I restriction enzyme, including a triple BstU I (5′-CGCGCG-3′)
site (Fig. 1). After BstU I cleavage, the PCR product amplified with wild DNA as a template
was completely digested to fragments at 246, 113 and lower combined signals at 61, 56 and
46 bp. The BstU I-digested fragments from bisulfite-modified DNA corresponded with those
of wild DNA in 70 μM choline (Fig. 1). However, the fragments from modified DNA in the 5
μM choline group contained a 359 bp band in addition to the bands of wild DNA; this band
corresponded to a DNA segment length of joined 246 and 113 bp bands. This 359 bp band was
only detected in cells grown in 5 μM (CD) and not in 70 μM (CT) choline, even if incubation
was extended to 72 h (data not shown).
To confirm these changes, bisulfite sequencing was used for a shorter sequence, due to the
limitations encountered in finding suitable priming sites for the bisulfite-modified DNA. The
CpG island spanning the position −408 to −125 contained 16 CpG sites, including the triple
CGCGCG site previously described (sites 12–14, Fig. 2). Three other CpG sites at the end of
the PCR product were excluded due to the frequent ambiguities in the sequencing process. In
all CD samples, most of the CpG sites were incompletely methylated (in a given sample, the
site was methylated on some strands but not on others; sites 4, 5, 7, 8, 9, 12, 13, 14, 15), with
the rest being inconstantly methylated or unmethylated. CT samples were extensively
methylated, with the majority of CpG sites being fully methylated. This confirms and extends
the changes observed using COBRA, where the choline-deficient DNA was partially digested.
To confirm these changes, the minus strand of the PCR products was also sequenced using the
anti-sense primers, as previously described. Samples from cells treated with 5-Aza were
markedly hypomethylated.
These changes in promoter methylation were associated with a change in CDKN3 gene
expression (Fig. 3) and in production of the KAP protein product (Fig. 4). The CD/CT ratio of
signal means for CDKN3 expression on DNA arrays was 2.649, the highest ratio among all
CDKNs and the only one above the arbitrary threshold of 2. The protein level of KAP by
western blotting was 2.4 times higher in CD- than in CT-treated cells (p < 0.01, Fig. 4 and
Table 1).
Decreased ppRb was observed in CD cells compared with CT cells (Fig. 4, 5 and Table 1). The
average IOD/cell ratio (CD/CT) for ppRb (phosphorylated pRb is the inactivated form) was
0.32 (p < 0.01 using t-test, n = 4 samples per condition; Fig. 4b, Table 1). The IOD/cell ratio
(CD/CT) for total pRb (CD/CT) was 0.688 (no statistical significance using the t-test, n = 4
samples per condition. The ratio (CD/CT) for expression of the Rb gene was 0.515 (DNA array
data).
Increased CDKN3 expression, production of KAP and decreased ppRb associated with choline
deficiency should result in decreased cell proliferation. The percentage of CT cells labeled with
BrdU was 1.8 times greater than in the CD cells after 48 h of incubation in their respective
defined media (p < 0.01; Table 1).
Discussion
We observed that choline deficiency in neuroblastoma cells was associated with inhibition of
cell proliferation. The progression through the cell division cycle depends on a process in which
cyclins sequentially bind and activate distinct cyclin-dependent kinases (Cdks). Cdks are
regulated by both transcriptional and post-translational mechanisms that promote the correct
timing and order of events for cell growth and cell division (Sherr 1994; Morgan 1997; Borriello
et al. 2002). In this study, oligonucleotide microarray analysis identified that CDKN3, a
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member of the cyclin-dependent kinase inhibitor group, was one of the genes that was
overexpressed in response to low choline in growth medium. CDKN3 encodes a Cdk-
interacting protein (KAP) mapped at 14q22 (Demetrick et al. 1995) where chromosome
abnormalities linked to several neoplasms have been located (Turc-Carel et al. 1988; Gilladoga
et al. 1992). KAP is a G1- and S-phase dual-specificity phosphatase that associates with Cdk2
(Hannon et al. 1994), and dephosphorylates a threonine residue (Thr160) in a cyclin A-
dependent manner (Poon and Hunter 1995; Brown et al. 1999). The selective inhibition of
Cdk2 reduces its ability to phosphorylate the pRb, which, in its non-phosphorylated form,
complexes with E2F1 transcription factor preventing it from binding to specific gene promoter
sites (Davies et al. 2002; Johnson et al. 2002). Cdk2 also drives the G1/S transition by
associating with the cyclins E and A (Johnson et al. 2002). Our results show that, indeed, less
choline-deficient cells undergo S-phase.
Choline and methyl-group metabolism are closely interrelated (Zeisel and Blusztajn 1994).
Therefore, it is not unexpected that choline availability alters global DNA methylation and the
methylation status of CpG islands in genes. Choline- and methyl group-deficient rodents had
diminished intracellular concentrations of AdoMet, the methyl donor used by DNA
methyltransferases (Zeisel et al. 1989). Others have reported that choline and methyl group
deficiency is associated with decreased global methylation of DNA (Pogribny et al. 1997;
Piyathilake et al. 2000) and decreased methylation of specific genes (Wu and Santi 1987;
Pogribny et al. 1997; Zhu and Williams 1998) in liver, lung and breast tissue.
The BstU I site located at 180–175 bp (-cgcgcg-) upstream from exon 1 starting site was not
fully methylated when cells were grown in 5 μM choline, but this methylation status was not
identical in all cells, as 246 and 113 bp fragments were still detected. These findings were
confirmed by the bisulfite-sequencing analysis, where a total of 16 CpG sites show
hypomethylation in the CD- and 5-Aza-treated cells compared with the control. The
heterogeneity in methylation between cells could be due to differences in cell–cell contact.
Neuroblastoma cells proliferate to form clusters of cells and then form neurites. It is possible
that the position of cells in the cluster, or the cell density in culture, may influence gene
methylation. In human fibroblasts and bladder cancer cells, confluence-induced growth
constraint is associated with transient alterations in CpG islands of specific genes (Pieper et
al. 1999; Velicescu et al. 2002).
We previously reported that changes in choline availability during pregnancy altered the rate
of stem cell proliferation in fetal brain (Albright et al. 1999a,b), and that this was, in part, the
result of changes in the localization of p15Ink4b and p27Kip1 in the fetal rat hippocampus,
two cyclin-dependent kinase inhibitors that modulate cell cycle progression (Albright et al.
2001). We now report that choline deficiency also modulates the expression of another cell
cycle inhibitor, KAP. Maternal dietary choline intake not only alters stem cell proliferation in
the fetal hippocampus, but also changes the size of the neurons in fetal septum (Loy et al.
1991), increases nerve growth factor concentrations in the fetal hippocampus (Sandstrom et
al. 2002), alters the electrophysiological properties of fetal hippocampus (Pyapali et al.
1998; Jones et al. 1999), and alters memory function in offspring throughout life (Meck et
al. 1988). Thus, formation of brain structures critical to memory formation, as well as
interactions between these structures in developing rat brain, are changed when cell cycle
regulation is perturbed by changes in maternal intake of a single nutrient, choline. Our study
suggests a mechanism whereby choline mediates these changes, via altered methylation of
promoter regions in the genes that regulate cell cycling.
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The promoter region of the CDKN3 gene is hypomethylated in choline-deficient IMR-32 cells.
After 48 h of incubation in CD (5 μM choline) or CT (70 μM choline) medium, cells were
lysed and DNA extracted. Genomic DNA (1 μg) was treated with sodium bisulfite followed
by PCR amplification of the region of interest and restriction digestion (COBRA analysis;
described in Experimental procedures). After this procedure, unmethylated CG sites transform
into TG, while methylated CG sites remain as CG. The inset diagram shows the cutting points
for BstU I restriction enzyme, which does not cut at TG sites but does cut at CG sites. Three
representative gels are presented from 5 replicates. Note that a band is present at 359 bp in CD,
and is not present in CT samples, indicating that the 5′-CGCGCG-3′ site upstream of exon 1
(indicated in the inset) is hypomethylated.
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CpG methylation status of CDKN3 promoter determined by bisulfite DNA sequencing. (a)
DNA sequence of the ‘284’ PCR product (wild-type DNA) compared with the sequence from
GenBank NT_025892. ‘N’ denotes ambiguous nucleotides. (b) Cells were incubated for 48 h
in CD medium (5 μM choline), CT medium (70 μM choline), or 70 μM choline + 5 μM 5-
azacytidine medium (5-Aza). Methylation maps obtained from sequencing four independent
samples for each condition. Sixteen CpG sites were mapped.
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Expression of cyclin-dependent kinase inhibitor (CDKN) genes determined by oligoarrays.
Cells were incubated for 48 h in CD medium (5 μM choline) or CT medium (70 μM choline).
Total RNA was extracted from six plates for each condition, reverse transcribed into cDNA
with Cy3 (70 μM choline as reference) or Cy5 (5 μM choline as experiment) monoreactive and
then hybridized to a Compugen 20 000 spot V2 Human Microarray. A total of three independent
experiments (three arrays) was performed.
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pRb and KAP protein expression in choline-deficient IMR-32 cells. After 48 h of incubation
in CD (5 μM choline) or CT (70 μM choline) medium, cells were lysed; the lysates were
subjected to electrophoresis and immunolabeled with a KAP or pRb antibody. β-actin was used
to control for protein loading. Images of membranes were scanned and the integrated optical
densities of the bands were measured and normalized to β-actin. The upper bands on the first
blot (pRb) denote the ppRb form, which was decreased in the CD cells.
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ppRb immunoreacivity in choline-deficient IMR-32 cells. After 48 h of incubation in CD (5
μM choline) or CT (70 μM choline) medium, cells were incubated with an antibody against
ppRb (p110) (Ser 249/Thr 252 specific). Phosphorylated pRb is localized mainly in the nucleus.
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Table 1
Changes in KAP protein, ppRb protein and BrdU accumulation in choline-deficient IMR-32 cells
Units CD CT
KAP Average IOD/lane 2650 ± 114* 1102 ± 123
ppRb (p110) Average IOD/cell 25376 ± 2999* 78146 ± 2809
BrdU Average %
incorporation positive cells 14.7 ± 1.1* 26.7 ± 2.0
Cells were incubated for 48 h in CD (5 μM choline) or CT (70 μM choline) medium. BrdU accumulation was assessed using immunohistochemical
methods described in Experimental procedures. KAP and phosphorylated Rb protein (ppRb) were determined using western blotting as described in the
legend to Fig. 4. The values are expressed as average ± standard error (n = 4 for each treatment).
*
p < 0.01 compared with CT.
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